Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam, Arrowhead Ink Cross-Licensing Agreement


Alnylam Pharmaceuticals and Arrowhead Research said this week that they have signed an agreement giving each other access to their respective RNAi drug technologies.

Under the deal, Alnylam gave Arrowhead access to its RNAi-related intellectual property for the development and commercialization of a treatment for hepatitis B. Alnylam stands to receive milestones and royalties through the arrangement.

Meantime, Arrowhead granted Alnylam the rights to use its dynamic polyconjugate delivery technology for an undisclosed RNAi drug. Alnylam said the candidate would likely be part of its Alnylam 5x15 initiative, which calls for the company to have five drugs against “genetically defined targets and diseases” in the clinic by 2015 (GSN 1/6/2011).

Arrowhead will be paid milestones and royalties on products Alnylam commercializes using the technology, which it acquired from Roche last year (GSN 10/27/2011).

Additional terms of the arrangement were not disclosed.

“We view Arrowhead’s DPC technology as a promising emerging delivery approach, with the potential to complement our existing delivery platform,” Alnylam CBO Laurence Reid said in a statement.

“This license from Alnylam is an important step for us as we expand our pipeline to include our first DPC-enabled candidate targeting hepatitis B,” Arrowhead President and CEO Christopher Anzalone added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.